HIMS Targets 100K Wegovy Monthly Prescriptions<\/p>\n
Dudum\u00a0said on X<\/a> that the company shipped its first Novo Nordisk medicines nearly two weeks ago as part of a \u201cstrategic shift\u201d in its weight-loss business and is already tracking toward a run rate of over 100,000 Wegovy prescriptions each month. \u201cMore treatment options mean more customers can find what works best for them,\u201d Dudum said.<\/p>\n The update comes after Novo dropped its patent-infringement lawsuit tied to Hims & Hers\u2019 earlier compounded GLP-1 offerings and instead reached an arrangement allowing the drugmaker to transition patients toward U.S. Food and Drug Administration (FDA) approved treatments.<\/p>\n Under the deal, Hims & Hers said it will discontinue marketing compounded GLP-1 alternatives and instead offer branded Wegovy alongside Ozempic for patients with Type 2 diabetes.<\/p>\n Eligible patients will have access to multiple Wegovy injection doses ranging from 0.25 milligrams to 2.4 milligrams, along with pill-based formulations across several doses. Ozempic injection pens will also be available in doses ranging from 0.25 milligrams to 2 milligrams for diabetes management.<\/p>\n Dudum\u2019s comments reinforce confidence in the company\u2019s outlook after CFO Yemi Okupe recently disclosed\u00a0plans to sell<\/a> up to 240,560 shares worth about $4.89 million under a pre-arranged Rule 10b5-1 trading plan, as Hims & Hers ramps its Novo Nordisk-backed GLP-1 rollout.\u00a0<\/p>\n HIMS Gets Boost From Novo Deal And Peptides Optimism<\/p>\n The update comes amid rising optimism around Hims as FDA officials are\u00a0reportedly\u00a0<\/a>moving to allow compounding pharmacies to manufacture more than a dozen injectable peptides that were restricted in 2023 over potential safety risks.<\/p>\n Last month, Barclays raised its price target on the stock to $29 from $25 and maintained an \u2018Overweight\u2019 rating, saying the Novo Nordisk deal removes a key legal uncertainty and reflects expanding opportunity tied to new product launches. Needham also said that the market may still be \u201cunderappreciating\u201d demand potential from cash-pay access to Wegovy pill formulations.<\/p>\n How Do Retail Traders Feel About HIMS?<\/p>\n On Stocktwits, retail sentiment for HIMS slipped to \u2018bearish\u2019 over the past week from \u2018bullish\u2019 levels a month ago amid \u2018extremely low\u2019 message volume.<\/p>\n One user\u00a0said<\/a> HIMS is \u201csignificantly undervalued with some estimates placing its intrinsic value as much as 66% to 75% higher than current trading levels. New highs in 2026 now possible\u201d<\/p>\n Another user\u00a0said<\/a>, \u201cThere\u2019s really no bear case here anymore. Literally none.\u201d<\/p>\n Over the past year, HIMS stock has declined nearly 30%.<\/p>\n For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n Read Next:\u00a0Nebius Stock On Hottest Streak In Nearly A Month, Retail Sentiment Climbs Amid Iran Volatility<\/a><\/p>\n![\"hims](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/04\/hims_ss_png_c15e7ee599.webp.png\")
HIMS sentiment and message volume as of April 8 | Source: Stocktwits<\/p>\n
![\"Follow](\"https:\/\/chunks-prd.stocktwits-cdn.com\/_next\/static\/media\/google-news-icon.d9c2bfd1.svg\"\/){kind=icon}
<\/a><\/p>\n